TABLE 4.
Susceptibilities to antimicrobial agents determined with the PHX system by the SST procedure compared to those determined with the PHX system with samples from pure cultures (phase III)
| Antibiotic | No. (%) of strains with:
|
|||
|---|---|---|---|---|
| Susceptibility results in agreement | Very major error | Major error | Minor error | |
| Amikacin | 309 | 0 | 0 | 0 |
| Gentamicin | 294 | 0 | 0 | 15 |
| Tobramycin | 309 | 0 | 0 | 0 |
| Imipenem | 306 | 0 | 0 | 3 |
| Meropenem | 309 | 0 | 0 | 0 |
| Cefuroxime | 297 | 2 | 1 | 9 |
| Cefpodoxime | 309 | 0 | 0 | 0 |
| Ceftazidime | 309 | 0 | 0 | 0 |
| Cefotaxime | 308 | 1 | 0 | 0 |
| Cefepime | 309 | 0 | 0 | 0 |
| Aztreonam | 309 | 0 | 0 | 0 |
| Amipicillin | 299 | 3 | 3 | 4 |
| Amoxicillin-clavulanate | 299 | 0 | 1 | 9 |
| Piperacillin | 299 | 1 | 1 | 8 |
| Piperacillin-tazobactam | 308 | 1 | 0 | 0 |
| Trimethoprim-sulfamethoxazole | 307 | 1 | 0 | 1 |
| Nitrofurantoin | 309 | 0 | 0 | 0 |
| Ciprofloxacin | 309 | 0 | 0 | 0 |
| Levofloxacin | 309 | 0 | 0 | 0 |
| Moxifloxacin | 309 | 0 | 0 | 0 |
| Total | 6,116 (99.0) | 9 (0.1) | 6 (0.1) | 49 (0.8) |